Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) received a $96.00 price objective from investment analysts at Credit Suisse Group in a research report issued on Tuesday, July 11th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 22.73% from the company’s current price.
A number of other research analysts have also weighed in on the stock. Morgan Stanley reaffirmed an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Needham & Company LLC reiterated a “buy” rating and issued a $98.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Chardan Capital restated a “buy” rating and set a $131.00 price objective (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 29th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $81.74.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 3.00% on Tuesday, hitting $78.22. The company’s stock had a trading volume of 847,539 shares. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The stock’s 50 day moving average price is $80.94 and its 200 day moving average price is $61.92. The stock’s market capitalization is $6.89 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 48.01% and a negative net margin of 670.81%. The firm’s revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.05) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals will post ($5.23) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.com-unik.info/2017/08/11/alnylam-pharmaceuticals-inc-nasdaqalny-given-a-96-00-price-target-by-credit-suisse-group-analysts-updated-updated-updated.html.
In other news, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares of the company’s stock, valued at approximately $393,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the sale, the senior vice president now directly owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. In the last three months, insiders sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in ALNY. Bank of Montreal Can raised its stake in Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 7,044 shares in the last quarter. Peregrine Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 7.5% in the first quarter. Peregrine Capital Management LLC now owns 221,909 shares of the biopharmaceutical company’s stock valued at $11,723,000 after buying an additional 15,477 shares in the last quarter. Macquarie Group Ltd. raised its stake in Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares in the last quarter. Opus Point Partners Management LLC raised its stake in Alnylam Pharmaceuticals by 97.0% in the fourth quarter. Opus Point Partners Management LLC now owns 88,784 shares of the biopharmaceutical company’s stock valued at $3,324,000 after buying an additional 43,720 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock valued at $2,755,000 after buying an additional 7,048 shares in the last quarter. 88.96% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
What are top analysts saying about Alnylam Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals Inc. and related companies.